Geographical variations in left main coronary artery revascularisation: a prespecified analysis of the EXCEL trial.


Journal

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
ISSN: 1969-6213
Titre abrégé: EuroIntervention
Pays: France
ID NLM: 101251040

Informations de publication

Date de publication:
28 Jan 2022
Historique:
pubmed: 3 7 2021
medline: 2 2 2022
entrez: 2 7 2021
Statut: ppublish

Résumé

The EXCEL trial reported similar five-year rates of the primary composite outcome of death, myocardial infarction (MI), or stroke after percutaneous coronary intervention (PCI) compared with coronary artery bypass grafting (CABG) for treatment of obstructive left main coronary artery disease (LMCAD). We sought to determine whether these outcomes remained consistent regardless of geography of enrolment. We performed a prespecified subgroup analysis based on regional enrolment. Among 1,905 patients randomised to PCI (n=948) or CABG (n=957), 1,075 (56.4%) were recruited at 52 European Union (EU) centres, and 752 (39.5%) were recruited at 67 North American (NA) centres. EU versus NA patients varied according to numerous baseline demographics, anatomy, pharmacotherapy and procedural characteristics. Nonetheless, the relative rates of the primary endpoint after PCI versus CABG were consistent across EU versus NA centres at 30 days and 5 years. However, NA participants had substantially higher late rates of ischaemia-driven revascularisation (IDR) after PCI, driven predominantly by the need for greater target vessel and lesion revascularisation. This culminated in a significant difference in the relative risk of the secondary composite outcome of death, MI, stroke, or IDR at 5 years (p In the EXCEL trial, the relative risks for the 30-day and five-year primary composite outcome of death, MI or stroke after PCI versus CABG were consistent irrespective of geography. However, five-year rates of IDR after PCI were significantly higher in NA centres, a finding the Heart Team and patients should consider when making treatment decisions. ClinicalTrials.gov identifier: NCT01205776.

Sections du résumé

BACKGROUND BACKGROUND
The EXCEL trial reported similar five-year rates of the primary composite outcome of death, myocardial infarction (MI), or stroke after percutaneous coronary intervention (PCI) compared with coronary artery bypass grafting (CABG) for treatment of obstructive left main coronary artery disease (LMCAD).
AIMS OBJECTIVE
We sought to determine whether these outcomes remained consistent regardless of geography of enrolment.
METHODS METHODS
We performed a prespecified subgroup analysis based on regional enrolment.
RESULTS RESULTS
Among 1,905 patients randomised to PCI (n=948) or CABG (n=957), 1,075 (56.4%) were recruited at 52 European Union (EU) centres, and 752 (39.5%) were recruited at 67 North American (NA) centres. EU versus NA patients varied according to numerous baseline demographics, anatomy, pharmacotherapy and procedural characteristics. Nonetheless, the relative rates of the primary endpoint after PCI versus CABG were consistent across EU versus NA centres at 30 days and 5 years. However, NA participants had substantially higher late rates of ischaemia-driven revascularisation (IDR) after PCI, driven predominantly by the need for greater target vessel and lesion revascularisation. This culminated in a significant difference in the relative risk of the secondary composite outcome of death, MI, stroke, or IDR at 5 years (p
CONCLUSIONS CONCLUSIONS
In the EXCEL trial, the relative risks for the 30-day and five-year primary composite outcome of death, MI or stroke after PCI versus CABG were consistent irrespective of geography. However, five-year rates of IDR after PCI were significantly higher in NA centres, a finding the Heart Team and patients should consider when making treatment decisions. ClinicalTrials.gov identifier: NCT01205776.

Identifiants

pubmed: 34212863
pii: EIJ-D-21-00338
doi: 10.4244/EIJ-D-21-00338
pmc: PMC9724945
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT01205776']

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

1081-1090

Références

Am Heart J. 2018 Jan;195:39-49
pubmed: 29224645
Eur Heart J Qual Care Clin Outcomes. 2017 Jul 1;3(3):243-248
pubmed: 28838095
Circ Cardiovasc Interv. 2017 May;10(5):
pubmed: 28495897
EuroIntervention. 2016 Sep 18;12(7):861-72
pubmed: 27639738
N Engl J Med. 2016 Dec 8;375(23):2223-2235
pubmed: 27797291
N Engl J Med. 2009 Feb 19;360(8):816-23
pubmed: 19228627
N Engl J Med. 2019 Nov 7;381(19):1820-1830
pubmed: 31562798
Circulation. 2018 Dec 18;138(25):2943-2951
pubmed: 30566019
Eur J Cardiothorac Surg. 2017 Sep 01;52(3):445-453
pubmed: 28520861
Eur J Cardiothorac Surg. 2015 May;47(5):855-9
pubmed: 25035414
Am Heart J. 2012 Sep;164(3):303-12
pubmed: 22980295
Circulation. 2010 Jun 22;121(24):2645-53
pubmed: 20530001
JAMA Cardiol. 2019 Feb 1;4(2):100-109
pubmed: 30601910
N Engl J Med. 2009 Mar 5;360(10):961-72
pubmed: 19228612

Auteurs

Aung Myat (A)

Sussex Cardiac Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom.
Division of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, United Kingdom.

David Hildick-Smith (D)

Sussex Cardiac Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom.

Adam J de Belder (AJ)

Sussex Cardiac Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom.

Uday Trivedi (U)

Sussex Cardiac Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom.

Aaron Crowley (A)

Clinical Trials Centre, Cardiovascular Research Foundation, New York, NY, USA.

Marie-Claude Morice (MC)

Hôpital Privé Jacques Cartier, Ramsay Générale de Santé, Massy, France.

David E Kandzari (DE)

Piedmont Heart Institute, Atlanta, GA, USA.

Nicholas J Lembo (NJ)

Clinical Trials Centre, Cardiovascular Research Foundation, New York, NY, USA.
NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, NY, USA.

W Morris Brown (WM)

Piedmont Heart Institute, Atlanta, GA, USA.

Patrick W Serruys (PW)

Department of Cardiology, National University of Ireland Galway (NUIG), Galway, Ireland.
Department of Cardiology, Imperial College London, London, United Kingdom.

Arie Pieter Kappetein (AP)

Thoraxcentre, Erasmus Medical Centre, Rotterdam, the Netherlands.

Joseph F Sabik (JF)

Department of Surgery, UH Cleveland Medical Center, Cleveland, OH, USA.

Gregg Stone (G)

Clinical Trials Centre, Cardiovascular Research Foundation, New York, NY, USA.
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH